<p>In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L to be associated with hearing loss in 390 non-cranial irradiated, cisplatin-treated children with cancer. These results were replicated in two independent, similarly treated cohorts. Modulating TCERG1L expression in cultured human cells revealed significantly altered cellular responses to cisplatin-induced cytokine secretion and toxicity. These results contribute to insights into the genetic and pathophysiological basis of cisplatin-induced ototoxicity.</p>

doi.org/10.1038/s41698-021-00178-z, hdl.handle.net/1765/136717
npj Precision Oncology
Erasmus MC: University Medical Center Rotterdam

A. J.M. Meijer, F. A. Diepstraten, T Langer, L. (Linda) Broer, I. K. Domingo, E (Eva) Timmermans - Clemens, … the CPNDS Consortium. (2021). TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. npj Precision Oncology, 5(1). doi:10.1038/s41698-021-00178-z